Molefuture and Ellis Bio Announce Strategic Partnership to Accelerate Global Biotech Innovation
2025-04-11 16:26
Shanghai, [2025.4.11] — Molefuture Biotechnology (Shanghai) Co., Ltd. (“Molefuture”) and Ellis Bio, Inc. (“Ellis Bio”) today announced a strategic partnership to drive innovation in life sciences and diagnostics.
The collaboration merges Molefuture’s advanced enzyme engineering platforms, including ZymeEditor™ and UCF.ME® Ultra-Clean Enzyme Production, with Ellis Bio’s cutting-edge reagent solutions, such as ultra-fast DNA methylation bisulfite conversion kits.
Ellis Bio, founded by University of Chicago Professor Chuan He, specializes in translating epigenetic research into high-performance products for cancer detection and aging studies. Molefuture’s expertise in enzyme design and GMP-grade manufacturing complements Ellis Bio’s reagent technologies, creating a powerful synergy to accelerate global biotech advancements.
Figure: A Corner of Ellis Bio's Laboratory
Leadership Statements
“Partnering with Molefuture enhances our ability to innovate and deliver transformative reagent solutions to global markets,” said Ruitu Lyu, CTO of Ellis Bio.“This collaboration leverages our complementary strengths to unlock new possibilities in biotechnology,” said Weihua Huang, CEO of Molefuture. “Together, we aim to redefine standards in diagnostics and life sciences.”
Statement: This article is an original advertising article. Please indicate the source link when reprinting: https://www.molefuture.com/en/h-nd-152.html
Enzyme Evolution Solution Provider
Tel：+86 13301688701 Email：Support@molefuture.com
Address：Building 3, No. 537 Qingdai Road, Pudong New District, Shanghai, China
Tel：+8613301688701
Email：Support@molefuture.com